EcoDrugPlus

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSLOCG00000004587
Gene Symbol: HTR3B
1 Cross references
173 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSLOCG00000012176
Gene Symbol: HTR4
3 Cross references
200 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSLOCG00000012511
Gene Symbol: HTR5A
3 Cross references
210 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSLOCG00000000025
Gene Symbol: HTR7
3 Cross references
220 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSLOCG00000005460
Gene Symbol: ABL1
1 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17a

Ensembl ID : ENSLOCG00000016828
Gene Symbol: ADAM17A
1 Cross references
282 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSLOCG00000010800
Gene Symbol: ADAMTS5
2 Cross references
199 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSLOCG00000012762
Gene Symbol: AKT1
2 Cross references
216 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSLOCG00000014670
Gene Symbol: AKT2
3 Cross references
253 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSLOCG00000007196
Gene Symbol: ABCC1
3 Cross references
201 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSLOCG00000002032
Gene Symbol: ABCC8
3 Cross references
242 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 9

Ensembl ID : ENSLOCG00000015376
Gene Symbol: ABCC9
3 Cross references
235 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).